Administering Cinaciguat at a dose of 10 mg/kg/day orally to diabetic rats does not alter blood glucose levels, however, it reduces water consumption. Cinaciguat treatment also mitigates oxidative stress related to diabetes mellitus, protects against alterations in the NO-sGC-cGMP-PKG pathway, and reduces myocardial hypertrophy and apoptosis associated with diabetes mellitus^[1].

Cinaciguat at concentrations of 1, 10, and 100 nM elicits concentration-dependent relaxations in gastrointestinal smooth muscle strips from both WT and apo-sGC mice, although it does not affect phasic activity caused by PGF2α in these muscle strips^[3].

Cinaciguat at 10 μM substantially boosts the production of intracellular cGMP, yet shows no dose-dependent impacts on cell contraction or calcium transient changes^[2].